Browse the evidence

There is a need to end disparities in cardiovascular morbidity and mortality related to race, sex, and income inequality.

Healthcare systems should implement strategies to reduce these disparities.

Semaglutide did not increase or reduce the risk of eye disorders (OR, 1.01; 95% CI, 0.91-1.12) or diabetic retinopathy (OR, 1.04; 95% CI, 0.92-1.17).

Semaglutide can be considered safe regarding eye disorders and diabetic retinopathy.

Dietary intake and biomarkers of total fat and saturated, monounsaturated, and polyunsaturated fatty acids were not associated with the risk of coronary events.

Practitioners should note that total fat and specific fatty acids do not appear to influence coronary event risk.

Challenges to scaling FIM programs include incorporating them into health care business models and educating the health care workforce.

Stakeholders should focus on developing business models and training programs to effectively scale FIM interventions.

Existing pharmacologic formulations for obesity have not provided optimal clinical efficacy and have had many concerning adverse effects.

Practitioners should be aware of the limitations and adverse effects of current obesity pharmacotherapies.

Statistical guidance and study designs are necessary to measure treatment response heterogeneity in nutrition and obesity research.

Researchers should adopt appropriate statistical methods and study designs to accurately assess treatment responses.

Semaglutide treatment is not associated with higher rates of short-term adverse events after cervical spine decompression and fusion in patients with Type 2 Diabetes Mellitus.

Practitioners can consider that semaglutide treatment does not increase short-term surgical risks in this patient population.

There are no statistically significant differences in the composite measure of postoperative surgical complications between semaglutide-treated patients and controls.

The findings suggest that semaglutide does not negatively impact surgical outcomes in this context.

The 30-day and 90-day readmission rates were similar between semaglutide-treated patients and controls.

This indicates that semaglutide does not increase the likelihood of readmission after surgery.

The most frequent adverse events associated with retatrutide were gastrointestinal, including nausea, diarrhea, and vomiting.

Clinicians should monitor for gastrointestinal side effects when prescribing retatrutide.

The approval of semaglutide by the FDA was based on the results of clinical trials.

Practitioners can inform patients that semaglutide is FDA-approved for weight management based on clinical evidence.

The cohort of 618 participants was successfully recruited despite challenges, exceeding the target of 600.

Successful recruitment strategies can be applied to similar trials.

Four nights of sleep restriction did not alter resting energy metabolism in postmenopausal women.

Practitioners can note that while insulin sensitivity and fat oxidation are affected, resting metabolism remains stable with sleep restriction.

Allowing Medicare coverage of anti-obesity medications could increase annual Part D costs by $3.1 billion or $6.1 billion depending on the percentage of newly eligible patients prescribed the drugs.

Practitioners should be aware of the potential financial implications of Medicare coverage for anti-obesity medications.

The marginal costs of Medicare coverage for anti-obesity drugs could decrease by up to 62.5% if products are approved for additional indications.

Practitioners should consider the potential for reduced costs if additional indications for anti-obesity drugs are approved.

The policy change of covering anti-obesity medications is likely to increase Medicare costs by low to middle tens of billions of dollars over ten years.

Practitioners should prepare for the potential long-term financial impact of Medicare's coverage of anti-obesity medications.

There were no significant changes in peak VO2 or other cardiovascular measures with HU6 treatment.

HU6 may not improve cardiovascular function despite weight loss.

25,215 adverse event reports related to tirzepatide were identified, predominantly in the 65 to 85 age group.

Healthcare providers should be aware of the high volume of AE reports in older adults using tirzepatide.

Novel adverse event signals include thyroid mass, medullary thyroid carcinoma, and conditions affecting the reproductive system and breast.

Clinicians should be vigilant for these specific adverse events in patients treated with tirzepatide.

There is limited clinical trial data on the safety and efficacy of anti-obesity medications for patients with heart failure.

Practitioners should be aware of the limited evidence when considering anti-obesity medications for heart failure patients.

The prevalence of obesity has increased markedly in recent decades, constituting major medical and socioeconomic problems worldwide.

Awareness of the obesity epidemic is crucial for public health initiatives.

There are currently no clear guidelines for the prehabilitation of obese patients with dysglycemia undergoing bariatric surgery.

Healthcare providers should recognize the need for developing guidelines for prehabilitation in this patient population.

Challenges in ensuring safety, tolerability, and equitable access are critical barriers to advancing anti-obesity pharmacotherapy.

Address these barriers to improve obesity treatment outcomes.

Obesity is projected to affect 3.8 billion people worldwide by 2050.

Practitioners should be aware of the increasing obesity trend and its implications for health.